Amalgamated Financial’s MaxCyte MXCT Stock Holding History

Amalgamated Financial’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$97K	Buy	+13,922	New	+$95K	﹤0.01%	2158

Other funds holding MXCT

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

DCP

D1 Capital Partners New York $11.2B AUM 15.78% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

RGI

River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Amalgamated Financial's MXCT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in MaxCyte (MXCT) in Q1 2022: 13,922 shares worth $97K. The stake represents ﹤0.01% of the portfolio and ranks #2158 among its holdings.

98 funds tracked by Wall St. Rank hold MXCT as of Q1 2022.

Amalgamated Financial held 13,922 shares of MaxCyte worth $97K as of Q1 2022.
MaxCyte was a new Amalgamated Financial position in Q1 2022.
MaxCyte made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2158 holding.
98 funds tracked by Wall St. Rank held MaxCyte as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.